Evidence check: LDL in the context of Wechseljahre

The link between LDL cholesterol and menopause is well-established: declining estrogen levels typically raise LDL, increasing cardiovascular risk. Evidence is human-strong (epidemiological and physiological studies). However, consumer DNA tests (e.g., MyBody-X) cannot reliably predict this rise – they provide only weak polygenic hints. A blood lipid panel is far more informative for individual risk assessment. Caveat: Menopause is a natural transition, but elevated LDL should be monitored by a physician, especially with other risk factors. Evidence for nutrigenetic tests in this context is marketing-based and not clinically validated.